BRCA Gene Mutation

Counseling Regarding Genetic Testing in Breast Cancer Lacking, Yet Many Still Undergo BLM

Counseling Regarding Genetic Testing in Breast Cancer Lacking, Yet Many Still Undergo BLM

By

Many women with breast cancer with genetic VUS undergo testing and bilateral mastectomy (BLM) without ever receiving genetic counseling.

Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location

Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location

By

Risk assessment study for carriers of the BRCA1/2 mutation identified the factors that influence their risk of developing breast cancer, ovarian cancer, or contralateral breast cancer.

Novel Approach Increases Breast, Ovarian Cancer Genetic Screening

Novel Approach Increases Breast, Ovarian Cancer Genetic Screening

By

A questionnaire added to intake forms at a breast cancer imaging center identified women with BRCA mutations who might otherwise have been missed.

Use of Counseling, Surgery Rates Show Limited Physician Knowledge of Breast Cancer Genetic Testing

Use of Counseling, Surgery Rates Show Limited Physician Knowledge of Breast Cancer Genetic Testing

By

Limited use of genetic counselors and high rate of double mastectomy in women at average risk with early-stage breast cancer illustrate that understanding of genetic testing results is limited.

Trends in BRCA Mutation Testing Shifting Toward Unaffected Women

Trends in BRCA Mutation Testing Shifting Toward Unaffected Women

By

Genetic testing for BRCA gene mutation is increasingly undertaken by women unaffected by breast and/or ovarian cancers.

<i>BRCA</i> Testing, Not Mastectomies, Show Increase After Jolie Editorial

BRCA Testing, Not Mastectomies, Show Increase After Jolie Editorial

More women tested for the BRCA genes but no corresponding increase in mastectomy rates

RANKL Inhibition May Represent Promising Breast Cancer Prevention Strategy

RANKL Inhibition May Represent Promising Breast Cancer Prevention Strategy

By

Research presented at 2016 SABCS showed whether RANKL inhibition could reduce the risk for developing breast cancer in BRCA1 mutation carriers.

Bi-allelic Inactivation Common in BRCA1 and BRCA Breast Cancers

Bi-allelic Inactivation Common in BRCA1 and BRCA Breast Cancers

By

Bi-allelic inactivation of BRCA1 and BRCA2 are frequent events in BRCA1 breast cancers and BRCA2 breast cancers, respectively, according to a study presented at SABCS 2016.

Study Identifies Patients Who May Derive More Benefit From Veliparib

Study Identifies Patients Who May Derive More Benefit From Veliparib

By

At SABCS 2016, researchers presented study findings demonstrating whether neoadjuvant treatment, PARPi-7, BRCAness, and MP1/2 predict response to veliparib plus carboplatin therapy in patients with high-risk breast cancer.

Novel Pathway Improves Access to Genetic Testing for Women With Ovarian Cancer

Novel Pathway Improves Access to Genetic Testing for Women With Ovarian Cancer

By

Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.

Prophylactic Gynecologic Resections Increase Risk for Aggressive Uterine Cancer in BRCA Gene Mutation Carriers

By

Women who carry the BRCA1 mutation are at increased risk for serous/serous-like endometrial carcinoma after risk-reducing salpingo-oophorectomy. Yet uncertainty exists over the need to perform a full hysterectomy in these women.

<i>BRCA1</i> Mutations May Raise Risk of Serous and Serous-Like Uterine Cancer

BRCA1 Mutations May Raise Risk of Serous and Serous-Like Uterine Cancer

Although overall risk for uterine cancer after risk-reducing salpingo-oophorectomy is not increased, the risk of serous/serous-like endometrial carcinoma is higher for BRCA1+ women.

Cell Changes in Fallopian Tubes of BRCA Mutation Carriers May Lead to Strategies for Preventing Ovarian Cancer

By

Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.

Research Shows Potential for Breast Cancer Prevention in BRCA1-Driven Tumors

Research Shows Potential for Breast Cancer Prevention in BRCA1-Driven Tumors

By

The drug denosumab, which blocks a bone gene, may also prevent breast cancer caused by a BRCA1 mutation. This already approved drug could be available quickly, and would be the first drug for breast cancer prevention.

BRCA1/2 Testing Recommendations Vary Between Black and White Patients

BRCA1/2 Testing Recommendations Vary Between Black and White Patients

By

Disparities in BRCA1/2 testing in black and white women is attributable to differences in physician recommendations, according to a recent study.

Nipple-sparing Mastectomy Safe for Women With High Risk of Breast Cancer

Nipple-sparing Mastectomy Safe for Women With High Risk of Breast Cancer

By

Prophylactic nipple-sparing mastectomy is as effective at preventing breast cancer as more invasive surgeries, according to a multi-institution study.

<i>BRCA1</i> Mutation May Reduce Women's Fertility

BRCA1 Mutation May Reduce Women's Fertility

The BRCA1 mutation may speed the aging of a woman's ovaries,according to a recent report.

Genetic Testing for BRCA Gene Mutations Increasing Among Younger Women With Breast Cancer

By

Among women age 40 years or younger, rates of genetic testing for BRCA1 and BRCA2 mutations have increased, according to a recent study.

<i>BRCA</i> Mutation Testing Rates on the Increase in Young Women

BRCA Mutation Testing Rates on the Increase in Young Women

Among young women diagnosed with breast cancer, frequency of testing 95 percent in 2013

Additional Genes Linked With Ovarian Cancer Risk Identified

By

The researchers found that nearly one fifth of women with ovarian cancer carried mutations in genes that were associated with ovarian cancer risk beyond the BRCA1 and BRCA2 genes.

Black women have higher frequency of BRCA mutations than previously reported

By

Young black women with a breast cancer diagnosis at age 50 years or younger have a much higher BRCA mutation frequency than that previously reported among young white women with breast cancer.

Higher frequency of <i>BRCA</i> mutations observed in black women

Higher frequency of BRCA mutations observed in black women

In a study reviewing black women under 50 with invasive breast cancer, 12 percent had BRCA1 or BRCA2 mutations.

Research identifies factors in 'Angelina Jolie effect' on breast cancer screening

Research identifies factors in 'Angelina Jolie effect' on breast cancer screening

By

Research indicates that Angelina Jolie's announcement that she had tested positive for BRCA1 influenced some women's intentions to seek out similar genetic testing.

BRCA-targeting drug has benefit in prostate cancer

By

Trials results indicate that the pioneering drug olaparib, which targets inherited mutations, can be beneficial for men with prostate cancer.

Genetic testing should be accessible to all women with ovarian cancer

By

Women with ovarian cancer should be tested for BRCA1 and BRCA2 gene mutations, regardless of their family history.

Oophorectomy may decrease in breast cancer death in women with cancer and BRCA1 mutation

By

Oophorectomy is linked to a 62% reduction in breast cancer death for women diagnosed with breast cancer that carry a BRCA1 gene mutation.

Risk of ovarian cancer may differ by type of BRCA1 or BRCA2 mutation

By

Researchers have identified mutations that were associated with significantly different risks of breast and ovarian cancers, which may have implications for risk assessment and cancer prevention decision making among carriers of these mutations.

Previvorship: Managing Cancer Risk Decisions in Unaffected BRCA-positive Women

Previvorship: Managing Cancer Risk Decisions in Unaffected BRCA-positive Women

By

Four major themes characterize the experience of cancer risk management for women who are positive for BRCA genetic mutations.

Magnetic resonance spectroscopy (MRS) shows precancerous breast changes in women with BRCA gene mutation

By

MRS that incorporates monitoring of biochemical changes in tissue could improve the management of women at risk of breast cancer, according to a new study.

Correlated spectroscopy pinpoints changes in <i>BRCA1/2</i> carriers

Correlated spectroscopy pinpoints changes in BRCA1/2 carriers

Lipid and metabolite deregulation were seen in breast tissue of women carrying BRCA1/2 mutations.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs